2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1037

Urinary C3d Is a Good Marker for Monitoring Treatment Response After 3 Months of Induction Treatment in Patients with Biopsy Proven Lupus Nephritis
Abstract Number: 2570

Urinary Cellular Profile as a Biomarker for Proliferative Lupus Nephritis
Abstract Number: 2629

Urinary Inflammatory Cell Analysis Reflects the Renal Histopathology in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Abstract Number: 690

Urinary MRP8/14, an Endogenous Toll-Like Receptor 4 Ligand, Reflects Renal Disease Activity in Lupus Nephritis: A Cross-Sectional and Longitudinal Assessment
Abstract Number: 1918

Urine CD163 Significantly Discriminates Active Lupus Nephritis and Strongly Correlates with Proliferative Glomerulonephritis
Abstract Number: 2637

Urine Complement Ba Levels During Flares of Renal Disease in Patients with ANCA-Associated Vasculitis
Abstract Number: 1118

US Community Rheumatologists’ Knowledge and Perceptions of Biosimilar Expanded Indication Approval by Extrapolation
Abstract Number: 549

US Rheumatologists’ Beliefs and Knowledge About Biosimilars – an Ongoing Survey
Abstract Number: 2059

Usage of Predicting Out-of-Office Blood Pressure Calculator in Hispanic Patients with Rheumatic Diseases
Abstract Number: 2394

Use and Influence of Biologic/Janus Kinase Monotherapy Among Recently Switched Rheumatoid Arthritis Patients: Results from an Annual National Patient Chart Audit
Abstract Number: 1861

Use of a Novel Electronic Auto-notification Process to Manage Transitions of Care in Rheumatic Patients on DMARD Therapy
Abstract Number: 161

Use of a Systematic Consensus Process to Inform Development of the Veterans Health Affairs Simulation Learning, Education and Research Network (SimLEARN) Musculoskeletal Clinician Course
Abstract Number: 2462

Use of Complementary and Alternative Medicine (CAM) in a Psoriatic Arthritis Cohort
Abstract Number: 2412

Use of Minimal Important Difference (MID) in Randomized Clinical Trials of Pain in Osteoarthritis
Abstract Number: 1672

Use of Rituximab for the Treatment of ANCA-Associated Vasculitis in Canada, 2010-2018

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].